Selecting appropriate treatments for maintenance therapy for bipolar disorder

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 5, 2008, Pages 28-35

  Thase, Michael E ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; METFORMIN; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; SIBUTRAMINE; TOPIRAMATE; VALPROATE SEMISODIUM;

ABNORMAL THINKING; ACNE; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HAND TREMOR; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCREASED APPETITE; KIDNEY INJURY; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MICTURITION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PANCREAS INSUFFICIENCY; PHARYNGITIS; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDE; THIRST; THROMBOCYTOPENIA; TREMOR; WATER RETENTION; WEIGHT GAIN; XEROSTOMIA;

AFFECT; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; LONG-TERM CARE; PATIENT EDUCATION AS TOPIC; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 56749096353     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Calabrese JR, Hirschfeld RMA, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003;64:425-432
2. Baldessarini R, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr 2006;11:465-471
3. Rihmer Z, Kiss K. Bipolar disorders and suicidal behaviour. Bipolar Disord 2002;4(suppl 1):21-25
4. Calabrese JR, Shelton MD, Rapport DJ, et al. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry 2002;63(suppl 10):18-22
5. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690
6. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006;57:660-665
7. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-1473
8. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005;7:307-325
9. Masand PS, Fazal FS, Patkar AA. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr 2004;9(11,suppl 12):16-26
10. Baptista T, Elfakih Y, Uzcategui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008;22:477-495
11. Young AH. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia. J Clin Psychiatry 2007;68(suppl 6):24-25
12. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67(suppl 9):25-30
13. Leonard BE. Clinical trials and their importance in assessing the efficacy and safety of psychotropic drugs. In: Leonard BE. Fundamentals of Psychopharmacology. 3rd ed. Chichester, United Kingdom: John Wiley and Sons; 2003:101-111
14. Colom F, Vieta E, Martinez A, et al. What is the role of psychotherapy in the treatment of bipolar disorder? Psychother Psychosom 1998;67:3-9
15. Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003;69:1101-1105
16. Baldessarini RJ, Tondo L. Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. Clin Drug Invest 1998;15:337-351
17. Biel MG, Peselow E, Mulcare L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Clin Drug Investig 1998;15:337-351
18. Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004;109:91-95
19. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217-224
20. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-117
21. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63:384-390
22. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol 2008;23(suppl 2):95-105
23. Pope M. Do clinicians understand why individuals stop taking lithium? J Affect Disord 2003;74:287-291
24. Gaudiano BA, Miller IW. Patients' expectancies, the alliance in pharmacotherapy, and treatment outcomes in bipolar disorder. J Consult Clin Psychol 2006;74:671-676
25. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry 2005;39:652-661
26. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-222
27. Maj M, Pirozzi R, Maglianp L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35
28. National Alliance of the Mentally Ill. About Mental Illness. Available at: http://www.nami.org/Template.cfm?Section=By_Illness&Template=/ TaggedPage/TaggedPageDisplay.cfm&TPLID=54&ContentID=23037&lstid = 325. Accessed May 8, 2008
29. Macritchie KA, Geddes JR, Scott J, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001;3:CD003196
30. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-489
31. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382
32. Revicki DA, Hirschfeld RM, Ahearn EP, et al. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. J Affect Disord 2005;86:183-193
33. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002;159(suppl 4):1-50
34. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400. Correction 2004;61:680
35. Calabrese JR, Bowden CL, Sachs G, et al, for the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024
36. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441
37. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-256
38. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-1290
39. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
40. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-1491
41. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
42. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269
43. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation vs antidepressant continuation on 1-year risk for relapse of bipolar disorder. J Clin Psychiatry 2001;62:612-616
44. Goodwin G, Vieta E. Effective maintenance treatment: breaking the cycle of bipolar disorder. Eur Psychiatry 2005;20:365-371
45. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br J Psychiatry 2004;184:337-345
46. Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008;69(suppl 5):9-15
47. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007;64:419-426